ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

WuXi Biologics to buy a Bayer facility in Germany

by Rick Mullin
January 24, 2020 | APPEARED IN VOLUME 98, ISSUE 4

 

WuXi Biologics will purchase a Bayer plant for finished biologic drugs in Leverkusen, Germany. In addition to being used by the Chinese pharmaceutical services firm, the plant will be a backup site for making Bayer’s Kovaltry, a recombinant antihemophilic factor. From its base in China, WuXi Biologics has expanded rapidly in recent years. It is building a $60 million biologics plant in Worcester, Massachusetts, and a $390 million facility in Dundalk, Ireland.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment